Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/srep32103 http://scihub22266oqcxt.onion/10.1038/srep32103 C5009379!5009379 !27586402     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=27586402 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\27586402 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Sci+Rep 2016 ; 6 (ä): 32103 Nephropedia Template TP {{tp|p=27586402 |t=2016. Long term outcome of Aldosteronism after target treatments |pdf=|usr=}}{{27586402 }} gab.com Text Long term outcome of Aldosteronism after target treatments JO: Sci Rep http://www.kidney.de/pget.php?&tw=1&pmid=27586402 #FOAvip There exists a great knowledge gap in terms of long-term effects of various surgical and pharmacological treatments on outcomes among primary aldosteronism (PA) patients. Using a validated algorithm, we extracted longitudinal data for all PA patients diagnosed in 1997-2010 and treated in the Taiwan National Health Insurance. We identified 3362 PA patients for whom the mean length of follow-up was 5.75 years. PA has higher major cardiovascular events (MACE) than essential hypertension (23.3% vs 19.3%, p?=?0.015). Results from the Cox model suggest a strong effect of adrenalectomy on lowering mortality (HR?=?0.23 with residual hypertension and 0.21 with resolved hypertension). While the need for mineralocorticoid receptor antagonist (MRA) after diagnosis suggests that a defined daily dose (DDD) of MRA between 12.5 and 50?mg may alleviate risk of death in a U-shape pattern. A specificity test identified patients who has aldosterone producing adenoma (HR?=?0.50, p?=?0.005) also confirmed adrenalectomy attenuated all-cause mortality. Adrenalectomy decreases long-term all-cause mortality independently from PA cure from hypertension. Prescription corresponding to a DDD between 12.5 and 50?mg may decrease mortality for patients needing MRA. It calls for more attention on early diagnosis, early treatment and prescription of appropriate dosage of MRA for PA patients. Twit Text FOAVip Long term outcome of Aldosteronism after target treatments ????Sci Rep http://www.kidney.de/pget.php?&tw=1&pmid=27586402 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27586402 #FOAvip English Wikipedia <ref>{{Cite pmid|27586402 }}</ref> Long term outcome of Aldosteronism after target treatments #MMPMID27586402 Wu VC ; Wang SM ; Chang CH ; Hu YH ; Lin LY ; Lin YH ; Chueh SC ; Chen L ; Wu KD Sci Rep 2016[Sep]; 6 (ä): 32103 PMID27586402 show ga There exists a great knowledge gap in terms of long-term effects of various surgical and pharmacological treatments on outcomes among primary aldosteronism (PA) patients. Using a validated algorithm, we extracted longitudinal data for all PA patients diagnosed in 1997-2010 and treated in the Taiwan National Health Insurance. We identified 3362 PA patients for whom the mean length of follow-up was 5.75 years. PA has higher major cardiovascular events (MACE) than essential hypertension (23.3% vs 19.3%, p?=?0.015). Results from the Cox model suggest a strong effect of adrenalectomy on lowering mortality (HR?=?0.23 with residual hypertension and 0.21 with resolved hypertension). While the need for mineralocorticoid receptor antagonist (MRA) after diagnosis suggests that a defined daily dose (DDD) of MRA between 12.5 and 50?mg may alleviate risk of death in a U-shape pattern. A specificity test identified patients who has aldosterone producing adenoma (HR?=?0.50, p?=?0.005) also confirmed adrenalectomy attenuated all-cause mortality. Adrenalectomy decreases long-term all-cause mortality independently from PA cure from hypertension. Prescription corresponding to a DDD between 12.5 and 50?mg may decrease mortality for patients needing MRA. It calls for more attention on early diagnosis, early treatment and prescription of appropriate dosage of MRA for PA patients. |Adrenalectomy [MESH] |Adult [MESH] |Female [MESH] |Humans [MESH] |Hyperaldosteronism/*diagnosis/drug therapy/*mortality/surgery [MESH] |Male [MESH] |Middle Aged [MESH] |Mineralocorticoid Receptor Antagonists/therapeutic use [MESH] |Propensity Score [MESH] |Proportional Hazards Models [MESH] |Taiwan/epidemiology [MESH]Long term outcome of Aldosteronism after target treatments (epmc).pdf DeepDyve Pubget Overpricing